Volume 1 - Supplement Issue 1: Abstracts of International Tehran Breast Cancer Congress                   Multidiscip Cancer Investig 2017, 1 - Supplement Issue 1: Abstracts of International Tehran Breast Cancer Congress: 0-0 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mansoori M, Mirzai A, Abdi Rad I, MahmoodLu R, Madjd Z. Expression of Ganglioside GD2, as a Novel Cancer Stem Cell Marker in Breast Carcinomas. Multidiscip Cancer Investig. 2017; 1
URL: http://mcijournal.com/article-1-99-en.html
Abstract:   (903 Views)
Introduction: Cancer stem cells (CSCs) are attractive for many researchers because of their diagnostic, prognostic and therapeutic implications. Here, we aim to investigate the local expression of Ganglioside GD2, as the recently proposed breast CSC (BCSC) marker, through the assessment of GD2 synthase mRNA, the key enzyme involved in GD2 synthesis.
Materials and Methods: Fresh tumor tissues along with normal adjacent tissues from 65 patients who underwent surgery for breast cancer were collected. Total RNAs of tumoral and normal tissue samples were extracted and analyzed using real-time PCR. The mRNA expression pattern of GD2 was compared in tumoral and control tissue samples using ΔΔCt method. The relevance of GD2 synthase level with clinical characteristics of the patients was also evaluated.
Results: The expression level of GD2 synthase was significantly higher in breast cancer tissue samples compared to normal adjacent tissues (4.92-fold change, P<0.001). GD2 synthase expression was also significantly higher in advanced grades tumor (2 and 3) (P=0.001) and in patients at stages III and IV compared to stages I and II (P=0.001). Whereas, the correlation between GD2 synthase and other clinicopathologic data was not statistically significant, such as for age (P=1.000), type of carcinoma (P=0.934), lymphatic invasion (P=0.139) and tumor size (P=0.066).
Conclusions: The higher expression of GD2 synthase in tumoral tissue samples of breast cancer patients further potentiates it as a BCSC marker which could be used for clinical implications such as diagnosis and prognosis of breast cancer.
Full-Text [PDF 107 kb]   (172 Downloads)    
Type of Study: Original/Research Article | Subject: genetics
Received: 2017/10/25 | Accepted: 2017/10/25 | ePublished: 2017/10/25

Add your comments about this article : Your username or Email:
Write the security code in the box

© 2018 All Rights Reserved | Multidisciplinary Cancer Investigation

Designed & Developed by : Yektaweb